Komori
General Meetings of Shareholders4559ZERIA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Shareholder Meeting Materials

At the 72nd Annual General Meeting of Shareholders, the Company will submit proposals to set the year-end dividend at ¥25 per share and to increase the number of directors from 6 to 7, electing 7 directors, including 4 outside directors. The annual dividend is expected to increase by ¥2 per share from the previous fiscal year.

Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
2
Yen per share (increase in annual dividend from the previous fiscal year)
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (72nd)
2026
Jun 26
Date and time28 days from this disclosure to the meeting
Matters for resolution2 items
  1. Appropriation of surplus

  2. Election of 7 Directors

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee
7Nominees
1New
4Outside
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (72nd)
Date and time10:00 a.m., Friday, 26 June 2026
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Election of 7 Directors
Shareholder ProposalNo
Director nominee7 candidates, including 1 new candidate and 4 outside directors
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The year-end dividend will be determined after comprehensively taking into account the results for the fiscal year, future business development and the business environment. As the terms of office of all directors expire, the Board will be expanded by 1 member to comprise 7 directors, including 4 outside directors.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 2026 Annual General Meeting of Shareholders and Shareholder Meeting Materials | ZERIA PHARMACEUTICAL CO.,LTD. (4559) timely disclosure | Komori